Oncolytics Biotech Inc. (ONC.TO)


Toronto - Toronto Delayed Price. Currency in CAD
0.36-0.00 (-1.37%)
At close: 2:49 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.38
Prev Close0.37
Bid0.36 x
Ask0.38 x
Day's Range0.36 - 0.38
52wk Range0.31 - 0.75
1y Target EstN/A
Market Cap43.44M
P/E Ratio (ttm)-3.30
Beta2.84
Volume9,000
Avg Vol (3m)74,629
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • CNW Group26 days ago

    Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

    Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

  • PR Newswire26 days ago

    Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

    CALGARY, Aug. 30, 2016 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (ONC.TO) (ONCYF) (ONY.F), will present at the 4th Annual Immuno-Oncology Summit in a session today, Tuesday, August 30th. The summit takes place from August 29th to September 2nd in Boston, MA. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

  • PR Newswire2 months ago

    MEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference

    CALGARY, Aug. 10, 2016 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (ONC.TO) (ONCYF) (ONY.F), will present at the 36th Annual Canaccord Genuity Growth Conference in a session on Thursday, August 11th, 2016 at 11:00 a.m. ET. The conference takes place on August 10th and 11th in Boston, MA. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.